Drugs / SK-NK injection
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT06991478 | May 2025 → May 2026 overdue | — | Tianjin Medical University Cancer Institute and Hospital | Not yet recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SK-NK injection | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06991478 ↗ |
| Modality | Cell therapy | “Allogeneic NK Cell Injection (SK-NK Injection)” NCT06991478 ↗ |
| Route | Intravenous | “receive intravenous infusion of SK-NK injection” NCT06991478 ↗ |